不同的腹腔热灌注化疗药物治疗晚期卵巢癌临床分析

发布时间：2018-10-18 18:24

【摘要】：目的:研究两组不同的腹腔热灌注化疗药物治疗晚期卵巢癌的近期疗效及不良反应。方法:将2013年7月至2015年11月76例晚期卵巢癌患者分为两组,单药组36例(肿瘤细胞减灭术后行腹腔热灌注5-氟尿嘧啶化疗联合静脉化疗)和联合用药组40例(肿瘤细胞减灭术后行腹腔热灌注5-氟尿嘧啶+卡铂化疗联合静脉化疗)。分析两组近期疗效、术后临床指标及静脉化疗后毒副反应。结果:单药组与联合用药组治疗后CA125有效率分别是86.11%,95.00%,差异有统计学意义(P0.05),腹水缓解率分别是97.22%,97.50%,差异无统计学意义(P0.05)。两组术后腹胀时间对比差异有统计学意义(P0.05)。两组患者药物不良反应比较:骨髓抑制、肝功损伤分布、胃肠道反应方面差异有统计学意义,两组患者肾功损伤分布、心血管系统损伤等方面差异无统计学意义。结论:术后腹腔热灌注化疗是晚期卵巢癌患者的有效辅助化疗手段,联合用药近期疗效明显,不良反应可耐受,临床可根据患者的具体情况选择。
[Abstract]:Objective: to study the short-term efficacy and adverse reactions of two groups of intraperitoneal hyperthermic infusion chemotherapy in the treatment of advanced ovarian cancer. Methods: from July 2013 to November 2015, 76 patients with advanced ovarian cancer were divided into two groups. There were 36 cases in the single drug group (intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy) and 40 cases in the combination group (intraperitoneal hyperthermic infusion of 5-fluorouracil carboplatin chemotherapy combined with intravenous chemotherapy). The short-term curative effect, postoperative clinical index and toxicity after intravenous chemotherapy were analyzed in both groups. Results: the effective rate of CA125 in the single drug group and the combination group was 86.119.00, the difference was statistically significant (P0.05), and the ascitic fluid remission rate was 97.22 ~ 97.50, respectively. The difference was not statistically significant (P0.05). The time of abdominal distension was significantly different between the two groups (P0.05). Comparison of adverse drug reactions between the two groups: bone marrow suppression, liver function injury distribution, gastrointestinal tract reaction differences were statistically significant, there was no significant difference in renal function injury distribution and cardiovascular system injury between the two groups. Conclusion: postoperative intraperitoneal hyperthermic infusion chemotherapy is an effective adjuvant chemotherapy method for patients with advanced ovarian cancer.
【作者单位】：郑州大学第二附属医院妇产科;
【基金】：河南省科学技术发展计划项目(编号:112102310505)
【分类号】：R737.31

【参考文献】